Tag: Servier

Servier Picked Yposkesi for Lentiviral Vector GMP-manufacturing in CAR-T Cell Development Technology...

Servier, an international independent pharmaceutical company, and Yposkesi, a leading CDMO for gene therapy viral vector manufacturing, announced that they have signed a manufacturing service agreemen...

Servier Launched the Production of a Drug for the Treatment of HIV infection

On April 25, the first production line of an innovative drug for the treatment of HIV infection in Russia was launched at the Servier pharmaceutical plant in Moscow. Alexander Prokhorov, Head of th...

Servier and Oncodesign Team Up for R&D Parkinson’s Drug

Servier, an international pharmaceutical company governed by a non-profit foundation, and biopharmaceutical company, Oncodesign have announced a strategic partnership for the research and development ...

Servier celebrated 15 years of operation in Georgia

French pharmaceutical group 'Servier' celebrated 15 years of operation in Georgia at an event attended by representatives of the Ministry of Health, industry specialists and company partners. The o...

The European Union’s General Court reduces cartel fine on Servier

The European Union’s General Court has reduced an EU fine on the French pharmaceutical company Servier

Servier and the Government of Kazakhstan agreed on cooperation

Servier, a French pharmaceutical company, and National Company KAZAKH INVEST JSC have signed an agreement on cooperation in the area of pharmaceutical manufacturing.

French company will set up a production of innovative medicines in Kazakhstan

At the meeting on global investments held in Astana, the companies of Kazakhstan signed 32 commercial documents for the total amount of $4.7 billion.

Manufacturing of Tivicay® in Moscow will be launched no later than May 2019

GSK and Servier signed an agreement to launch the manufacturing of innovative HIV drug Tivicay® (INN: dolutegravir) in the production facility of Servier Rus pharmaceutical plant in Moscow.

Servier introduced its new Effient drug to the Russian market

Servier announced that sales of Effient®, its innovative last-generation antiplatelet agent, began in Russia in March 2018. The license agreement covering the territory of Russia was signed with Daiichi Sankyo in July 2016.

Servier buys oncology business from Shire

Shire, the leading global biotechnology company focused on rare diseases announced that it has entered into a definitive agreement with to sell its Oncology business for $2.4 billion.

ImmunoQure enters into exclusive partnership with Servier

ImmunoQure, a German biotech company, and the international pharmaceutical company Servier announced the establishment of an exclusive partnership for the development of a therapeutic autoantibody neutralizing interferon-alpha.

Servier upgrades its logistical capacity in Russia

Servier has officially launched its new logistical platform in Russia. It began to operate at the facilities of Santens Service Group

ViiV Healthcare localizes the manufacturing of dolutegravir in Russia

viiv healthcare
Three registration lots of dolutegravir manufactured at Servier Pharmaceutical Plant in Russia successfully passed stability tests and comparative dissolution kinetics tests

Servier launches a new high-tech facility in Russia

As part of events held to mark the 10th anniversary of its pharmaceutical plant in Russia, Servier launched a new high-tech process to manufacture the medicinal products.

Servier and CTI BioPharma extended their collaboration

Servier and CTI BioPharma Corp. jointly announced that they agreed to expand their existing license and development collaboration agreement for PIXUVRI (pixantrone). Under this expanded agreemen...

Servier will manufacture an oral anticoagulant in Russia

Servier JSC and Daiichi Sankyo Europe have signed a strategic license agreement under which Servier JSC received the rights to manufacture/package edoxaban, an oral anticoagulant, at its pharmaceutica...